MENASHE BAR ELI to Imatinib Mesylate
This is a "connection" page, showing publications MENASHE BAR ELI has written about Imatinib Mesylate.
Connection Strength
0.156
-
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood. 2008 Mar 01; 111(5):2904-8.
Score: 0.057
-
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5.
Score: 0.044
-
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 2002 Nov; 8(11):3584-91.
Score: 0.040
-
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.
Score: 0.015